Zynga price target raised to $10 from $9 at JPMorgan 10/26 ZNGA JPMorgan analyst Alexia Quadrani raised the firm's price target on Zynga to $10 from $9 and keeps an Overweight rating on the shares. The video game publishers continue to benefit from heightened engagement and spending during the pandemic as other forms of entertainment remain on hiatus, Quadrani tells investors in a research notel.
Van, Nastassia dropped off some notes on Zynga and she said " You Think It's Easy " and she left me this:
I have tried to explain to my wife but she doesn't really get the subtleties of Nastassia. Sometimes it's the cool stare psych out. Sometimes it's the I'm so damn sexy psych out. Sometimes it's the Marine yell. Sometimes the third eye stroke and every once in a while she just rocks out and gets the fans pumped up. I plan to suggest Minsk, Belarus as our first family trip after Covid.
I told her yesterday... "A little less track time and a little more 'Gummy of the Day' submissions". I'm not fluent in Russian profanities, but judging by the inflection in her voice, I don't think she was too pleased. Where's my Gummy?!
Van I feel frozen by the market. Not willing to gamble on pot stocks. Worried equally about a big sell off and a big rally not sure either would be good. Georgia senate race apparently is very important. If that goes Democratic then chances for Senate switch to Dem is there and that means more stimulus which means market rally. GRWG- TT- CARR- Van I think you have a play setting up in ZNGA. I really don not get it but video gaming is one of these sectors I am most convinced on as kids are home alot more. I do not own anything in the space... Tragic Sony sell but I did make alot... Nov 4 earnings--- Zynga Limited entertainment opportunities during the pandemic have led to great results from video game stocks, andZynga(NASDAQ:ZNGA)has been in the sweet spot of mobile and social games to fill a void in consumer lives. Acquisitions, internally developed titles, and improved monetization spurred by live events is driving rapid expansion of the company's business, and that trend should continue. Revenue in the second quarter ballooned 47% year over year, beating the company's guidance. Daily active users (DAUs) grew 4% from the year before to 22 million, but revenue gains are coming from increased spending by those users, largely a consequence of the popularity of Zynga's live events. Average bookings per mobile average user was $0.248, up 32% from a year ago and above the $0.216 in Q1. Zynga's acquisitions are an important part of its growth strategy, and the company has plenty of cash to snap up new expansion opportunities. The purchase of 80% of Rollic for $168 million in August allows it to enter the hyper-casual game segment, pick up another 5 million DAUs, and boost its advertising revenue, which has been declining this year. Zynga had $1.3 billion in cash on its balance sheet last quarter, so investors can expect plenty more acquisitions in the future. Looking forward, Zynga, which reports earnings on Nov. 4, expects full year revenue of $1.8 billion and bookings of $2.2 billion, growth of 36% and 41%, respectively. Although the company is not yet profitable, it sells for 3.7 times analyst estimates of 2021 bookings,very reasonable for this sort of growth. Look at the YTD chart you could argue the slope of the uptrend portends decently higher prices... around $12. Sounds like Earnings should be good.. Certainly watch list.! ZYNGA would be my Gummy Of The Day esp at $8.98-$9.00 It's only $9.23 now....~si
I'm having a vague PTSD moment with Covanta I'm sure I played this back in the day for something. It had an interesting Friday! Look at the 2 day! ooompha. Covanta Holding Corporation (CVA) NYSE - Nasdaq Real Time Price. Currency in USD 10.14+1.06 (+11.67%) As of 11:25AM EST. Market open.
This is tricky-- Humanigen executes lenzilumab licensing deal in Asia for COVID-19 Nov. 3, 2020 7:54 AM ET|About: Humanigen, Inc. (HGEN)| Humanigen (NASDAQ:HGEN) perks 7% premarket after executing its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical, Inc. and KPM Tech Co., Ltd for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines. Telcon and KPM Tech, both recently invested in HGEN June 2020 PIPE offering. Agreement provides Humanigen up to $20M in milestones and double-digit royalties on product sales. Telcon and KPM Tech will be responsible for gaining regulatory approval and subsequent commercialization of lenzilumab in its territories. So you invest in a stock and then give that stk a large purchase order///// sketchy.
Our favorite value tech play executes!-- without even looking I'm going to say the stock trades at $38! Silicon Motion tops Q3 estimates, forecasts upside revenue on SSD controller strength Nov. 3, 2020 7:44 AM ET|About: Silicon Motion Technology C... (SIMO)| Silicon Motion (NASDAQ:SIMO) shares were up 3% in late trading after yesterday's Q3 beats with an upside Q4 revenue forecast. SSD controller sales increased about 20% on the quarter and the year. eMMC+UFS controller sales fell about 50% Q/Q and about 10% Y/Y due to an expected temporary customer inventory adjustment. SSD solutions sales were softer than expected, declining about 10% sequentially and increased about 50% Y/Y. “We expect our fourth quarter revenue to rebound as SSD controller sales strengthen further,” says CEO Wallace Kou. “In addition, our eMMC+UFS controllers are making good progress towards recovery in the fourth quarter while SSD solutions are expected to be seasonally down. We expect our fourth quarter to be a solid finish to an unpredictable year and a good foundation for a stronger 2021.” For Q4, SIMO expects $130-139M in revenue (+3-10% Q/Q, consensus: $128.5M), 47.9-49.9% gross margin, and 12.3-14.4% gross margin.